Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750727 | 0.92 | USP30 (0.45) | USP30JAK2JAK3PTK2HPGDS | |
| SCHEMBL20551736 | 0.91 | JAK2 (0.52) | USP30JAK2JAK3PTK2HPGDS | |
| SCHEMBL20551540 | 0.88 | TP53 (0.50) | USP30HPGDSACKR3PRMT5APLNR | |
| SCHEMBL21750810 | 0.88 | TP53 (0.50) | USP30HPGDSACKR3PRMT5APLNR | |
| SCHEMBL20551893 | 0.84 | HTT (0.49) | USP30HPGDSACKR3PRMT5APLNR | |
| SCHEMBL21750686 | 0.84 | HTT (0.49) | USP30HPGDSACKR3PRMT5APLNR | |
| SCHEMBL21750805 | 0.80 | GRM1 (0.46) | JAK2JAK3PTK2 | |
| SCHEMBL31379880 | 0.79 | JAK2 (0.56) | USP30JAK2JAK3PTK2HPGDS | |
| SCHEMBL20552488 | 0.79 | ACP1 (0.40) | JAK2JAK3PTK2ACP1 | |
| SCHEMBL31310816 | 0.79 | ACP1 (0.40) | JAK2JAK3PTK2ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-23 | — | — | US | disclosed |
| EP-3825310-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2025-11-12 | — | — | EP | disclosed |
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-04-09 | — | — | US | disclosed |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2022-08-04 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | CDC42, RHOA, TNK2 | USP30 4340/4885JAK2 2831/4885JAK3 2979/4885 |
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | TNK2, CDC42, CDC42BPA | USP30 4671/4885JAK2 1213/4885JAK3 1183/4885 |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | USP30 4684/4885JAK2 4468/4885JAK3 4374/4885 |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | CDC42, TNK2, ARHGEF1 | USP30 4640/4885JAK2 2881/4885JAK3 2979/4885 |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | USP30 4684/4885JAK2 4468/4885JAK3 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.